Evidence map›Paper›PMID 31292842›Full record

ArticleClinical journal of gastroenterology2020

A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection.

Akio Miyasaka, Yuichi Yoshida, Akiko Suzuki, Hironobu Ueda, Yoshihiro Morino, Yasuhiro Takikawa

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Akio MiyasakaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 020-8505, Japan. akimiya@iwate-med.ac.jp.ORCID http://orcid.org/0000-0001-7747-5977
Yuichi YoshidaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 020-8505, Japan.
Akiko SuzukiDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 020-8505, Japan.
Hironobu UedaDivision of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan.
Yoshihiro MorinoDivision of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan.
Yasuhiro TakikawaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 020-8505, Japan.
Iwate Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 44-year-old woman with chronic hepatitis C virus (HCV) infection was referred by a primary care doctor and admitted to our hospital because of worsening dyspnea on exertion and right atrial and ventricular enlargement. The patient was diagnosed with pulmonary arterial hypertension (PAH) associated with portal hypertension induced by chronic HCV infection. This diagnosis was based on a cardiological examination and findings related to liver cirrhosis with portal hypertension. After the prescription of anti-PAH medicine and a slight improvement in her respiratory symptoms, 12-week direct-acting antiviral (DAA) treatment for HCV was started. Serum HCV RNA levels rapidly decreased and HCV elimination was confirmed 24 weeks after completing DAA treatment. Before confirmation of a sustained virological response at 24 weeks after completing DAA treatment, a remarkable improvement in her cardiac markers was found in a right heart catheter study. This study was performed 6 weeks after the end of DAA administration. Therefore, we considered that HCV infection was involved in the development of PAH and that elimination of HCV by interferon-free treatment was important for this patient.

Indexed as

AdultAntiviral AgentsCardiac CatheterizationEchocardiographyEchocardiography, DopplerEndothelin Receptor AntagonistsFemaleHepatitis C, ChronicHumansHypertension, PortalLiver CirrhosisPhosphodiesterase 5 InhibitorsPulmonary Arterial HypertensionPyrimidinesSulfonamidesSustained Virologic ResponseAntiviral AgentsEndothelin Receptor AntagonistsmacitentanPhosphodiesterase 5 InhibitorsPyrimidinesSulfonamidesTadalafilDirect-acting antiviralsHCV infectionPortal-pulmonary hypertensionPulmonary hypertension

Identifiers

PMID31292842
OpenAlexW2960327977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.